BIT

0.00%

1.9¢ biotron limited

BIT036- a likely candidate for curing COVID-19, page-947

First 947 Last

Share
Profile

Follow
Thaliat

4,929 Posts.

836

18/12/21

21:45

Post #: 58390070
Share

Originally posted by Batmansdaughter: ↑

If you read the WHO document above, you will note the limitations of drugs that target a sole cytokine, suck as IL-6

an extract
The prospective and living network meta-analyses showed that in severely or critically ill patients, administering these drugs reduce the odds of death by 13%, compared to standard care. This means that there will be 15 fewer deaths per thousand patients, and as many as 28 fewer deaths for every thousand critically ill patients. The odds of mechanical ventilation among severe and critical patients are reduced by 28%, compared with standard care. This translates to 23 fewer patients out of a thousand needing mechanical ventilation.

If BIT225 can replicate in humans what it achieved in ACE2 mice, then there will be only one drug on everybody's lips (and in their gut).

The interesting thing is that we will know quite soon, relatively speaking, At least any interim results, The next Q is going to be very insightful.

Do you recall at the beginning of the pandemic how it was often said that vaccines 'take 10 years' to develop............. yet came about in one.

BIT225 only has to have one human trial, which it can go staright into because of its high safety profile.

What do you think the FDA is doing now with this recent Covid in vivo mouse and culture data for Delta from Biotron, with all its HIV safety data, not to mention the relationship between HIV and C-19 viroporin activity?

They won't be putting it in the bottom draw and saying, maybe one day. They will be analyzing it al pronto.

I believe we are going to hear about the commencement of huiman trials in the very, very near future.

Don't invest more than you are prepared to lose, and don't listen to bats, as it might be a conspiracy considering SARS2 originated with them.

Expand

Christmas present anyone? CTAP announcement imminent......

Ahhhhh feet up and grab another G&T

BIT Price at posting: 9.1¢ Sentiment: Buy Disclosure: Held
9 Upvote

1 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

There are more pages in this discussion • 1,120 more messages in this thread...

First 947 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $17.14M

Open	High	Low	Value	Volume
1.9¢	1.9¢	1.9¢	$7.664K	403.3K

Buyers (Bids)

No.	Vol.	Price($)
1	100000	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	1202498	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.019
10	1774771	0.018
10	1139476	0.017
12	3734154	0.016
10	1205000	0.015

Price($)	Vol.	No.
0.020	1052498	3
0.021	500000	1
0.022	1431102	4
0.023	1100772	2
0.024	153949	2

Last trade - 13.42pm 27/09/2024 (20 minute delay)

BIT (ASX) Chart

BIT036- a likely candidate for curing COVID-19, page-947

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

BIT036- a likely candidate for curing COVID-19, page-947

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News